Prism VentureWorks has promoted Brendan O'Leary to general partner. He joined the firm in 2003, and co-leads the firm's life sciences practice. His board seats include Locus Pharmaceuticals, Proteon Therapeutics, ROX Medical, Serica Technologies and Trius Therapeutics.
Prism VentureWorks, an early-stage venture capital firm focused on Digital Media, Software & Services and Life Sciences, today announced Brendan O'Leary has been promoted to General Partner. Dr. O'Leary joined Prism in 2003 and co-leads the firm's Life Sciences practice.
“Dr. O'Leary is responsible for Prism's major portfolio win in BioRexis Pharmaceutical Company, a therapeutics company which was acquired by Pfizer (NYSE:PFE) in February, 2007. His foresight has been instrumental in strengthening and expanding Prism's Life Sciences practice. Brendan brings considerable domain expertise in identifying disruptive segments within the medical technology and therapeutics fields and excels at working with the finest entrepreneurs to grow successful businesses,” said General Partner Gordie Nye.
Dr. O'Leary currently serves on the boards of Prism portfolio companies Locus Pharmaceuticals, Proteon Therapeutics, ROX Medical, Serica Technologies and Trius Therapeutics.
Prior to joining Prism, he held several leadership positions within IGEN International, a leading medical diagnostics company that was acquired by Roche in 2003 for $1.3 billion, and Meso Scale Discovery, an IGEN-spinout focused on high throughput drug discovery. He is a respected scientist with numerous inventions, publications, and commercialized products to his credit. Dr. O'Leary received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and holds a B.A. in Chemistry and Economics from
About Prism VentureWorks
Prism VentureWorks is an early-stage venture capital firm focused on disruptive segments in the Digital Media, Software & Services and Life Sciences sectors. The firm represents a committed team of early-stage investors whose industry operating heritage and domain depth make them valued partners among entrepreneurs and syndicates in building successful businesses.
Founded in 1996, the Firm has approximately $1.25 billion in capital under management with offices in